drugset / Trial / NCT00607308

A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease

NCT00607308 ↗

Phase 1 Completed 20 enrolled Pfizer
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to examine the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a single dose of PF-04360365 in Japanese subjects with mild to moderate Alzheimer's Disease.

Timeline

Start
2008-02
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ponezumab Monoclonal antibody 0.1 mg/kg Intravenous
Subject Ponezumab Monoclonal antibody 0.5 mg/kg Intravenous
Subject Ponezumab Monoclonal antibody 1 mg/kg Intravenous
Subject Ponezumab Monoclonal antibody 5 mg/kg Intravenous
Subject Ponezumab Monoclonal antibody 10 mg/kg Intravenous

Indications